Cancer protective mutations: Looking for the needle in the haystack

Clinical and Translational Oncology

Volumn 3, Issue 4, 2001, Pages 169-171

  Pérez Graciaa, José Luis ^a   Ruiz Ilundáinb, María Gloria ^b  

^a ELI LILLY AND COMPANY   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952168891     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1.233-1.238.
2. Benedict WF, Murphree AL, Banerjee A, Spina CA, Sparkes MC, Sparkes RS. Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 1983; 219: 973-975.
3. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-784.
4. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
5. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1.684-1.689.
6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 correceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
7. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
8. Quillent C, Oberlin E, Braun J, et al. HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351: 14-18.
9. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
10. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-780.
11. Gambaro G, Anglani F, D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet 2000; 355: 308-311.
12. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 12.810-12.815.
13. Chen J, Giovanucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4.862-4.864.
14. Ma J, Stampfer MJ, Giovanucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1.098-1.102.
15. London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 2000; 28: 147-155.
16. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism ad lung cancer risk. Cancer Res 1997; 57: 5.001-5.003.
17. Schabath MB, Spitz MR, Zhang X, Declos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 2000; 21: 1.163-1.166.
18. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463G?A polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9: 181-184.
19. Cascorbi I, Henning S, Brocmoller J, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463 A of the myeloperoxidase gene. Cancer Res 2000; 60: 644-649.
20. Chen H, Lum A, Seifried A, Wilkens LR, Le Machand L. Association of the NAD(P)H:quinone oxidoreductase 609C?T polymorphism with a decreased lung cancer risk. Cancer Res 1999; 59: 3.045-3.048.
21. Harth V, Donat S, Ko Y, Abel J, Vetter H, Brunning T. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. Arch Toxicol 2000; 73: 528-531.
22. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350: 630-633.
23. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998; 58: 5.291-5.293.
24. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 2000; 10: 105-114.
25. Christensen PM, Gotzsche PC, Brosen K. The sparteine/ debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J ClinPharmacol 1997; 51: 389-393.
26. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998; 8: 227-238.
27. Milner BJ, Brown I, Gabra H, Kitchener HC, Parkin DE, Haites NE. A protective role for common p21WAF1/Cip1 polymorphisms in human ovarian cancer. Int J Oncol 1999; 15: 117-119.
28. Houlston RS. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 1999; 8: 675-682.
29. Ozdemir E, Kakehi Y, Nakamura E, et al. HLADRB1 0101 and 0405 as protective alleles in Japanese patients with renal cell carcinoma. Cancer Res 1997; 57: 742-746.
30. Ichimiya M, Muto M, Hamamoto Y, Ohmura A, Tateno H, Asagami C. Putative linkage between HLA class I polymorphism and the susceptibility to malignant melanoma. Australas J Dermatol 1996; 37 (Supl 1): S39.
31. Tokumoto H. Analysis of HLA-DRB1-related alleles in Japanese patients with lung cancer-relationship to genetic susceptibility and resistance to lung cancer. J Cancer Res Clin Oncol 1998; 124: 511-516.
32. Dunning AM, Chiano M, Smith NR, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet 1997; 6: 285-289.